LUV TRZ2

A 39-residue acylated synthetic peptide characterized in receptor-binding and cryo-EM structural studies of class B GPCR complexes.

Molecular Profile

Type
Synthetic linear peptide (acylated, 39 residues)
Molecular formula
C225H348N48O68
Molecular weight
~4,814 g/mol
CAS number
2023788-19-2
Amino acids
39
Fatty acid chain
C20 diacid (icosanedioyl) at Lys20
Modification
Positions 2 and 13 are α-aminoisobutyric acid (Aib); Lys20 bears an Nε-conjugated γ-Glu-(AEEA)₂ linker with a C20 fatty diacid (icosanedioyl); C-terminal Ser is amidated.

Mechanism & Target Class

A 39-residue synthetic peptide. Positions 2 and 13 are α-aminoisobutyric acid (Aib), conferring resistance to enzymatic degradation by DPP-4; the C20 fatty-diacid chain at Lys20 promotes reversible albumin binding, extending circulatory half-life. Cryo-EM studies have characterized how the N-terminal region engages the orthosteric site of its class B G protein–coupled receptor targets via hydrogen bonds and ionic interactions.

Storage & Handling

Lyophilized
-20°C (-80°C long term); powder typically stable ~24 months.
Handling
Aliquot to avoid freeze-thaw; protect from light; keep sealed and dry.

Primary Database

PubChem CID 163285897 ↗

References (22)

  1. Reviews

    1

    Galindo RJ, Cheng AYY, Longuet C, et al. (2026). Diabetes Ther

    DOI: 10.1007/s13300-025-01804-w

  2. 2

    Nauck MA, D'Alessio DA (2022). Cardiovasc Diabetol

    DOI: 10.1186/s12933-022-01604-7

  3. 3

    Sun B, Li Z, Xiao Y, et al. (2022). Nat Rev Drug Discov

    DOI: 10.1038/s41573-022-00177-5PubMed 35818715

  4. 4

    Min T, et al. (2021). Diabetes Ther

    DOI: 10.1007/s13300-020-00981-0PubMed 33325008

  5. 5

    Nowak M, et al. (2022). Endokrynol Pol

    DOI: 10.5603/EP.a2022.0029PubMed 35593668

  6. 6

    Forzano I, et al. (2022). Int J Mol Sci

    DOI: 10.3390/ijms232314631PubMed 36498958

  7. 7

    Tang Y, et al. (2022). Front Pharmacol

    DOI: 10.3389/fphar.2022.1016639PubMed 36569320

  8. 8

    Bhagavathula AS, et al. (2021). Pharmaceuticals (Basel)

    DOI: 10.3390/ph14100991PubMed 34681215

  9. 9

    Campbell JE, et al. (2023). Cell Metab

    DOI: 10.1016/j.cmet.2023.07.010PubMed 37591245

  10. Clinical

    10

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). N Engl J Med

    DOI: 10.1056/NEJMoa2206038PubMed 35658024

  11. 11

    Frias JP, Davies MJ, Rosenstock J, et al. (2021). N Engl J Med

    DOI: 10.1056/NEJMoa2107519PubMed 34170647

  12. 12

    Frias JP, et al. (2018). Lancet

    DOI: 10.1016/S0140-6736(18)32260-8PubMed 30293770

  13. 13

    Ludvik B, et al. (2021). Lancet

    DOI: 10.1016/S0140-6736(21)01443-4PubMed 34370970

  14. 14

    Del Prato S, et al. (2021). Lancet

    DOI: 10.1016/S0140-6736(21)02188-7PubMed 34672967

  15. 15

    Dahl D, et al. (2022). JAMA

    DOI: 10.1001/jama.2022.0078PubMed 35133415

  16. 16

    Garvey WT, et al. (2023). Lancet

    DOI: 10.1016/S0140-6736(23)01200-XPubMed 37385275

  17. Primary research

    17

    Sun B, Willard FS, Feng D, et al. (2022). Proc Natl Acad Sci U S A

    DOI: 10.1073/pnas.2116506119PubMed 35333651

  18. 18

    Willard FS, Douros JD, Gabe MBN, et al. (2020). JCI Insight

    DOI: 10.1172/jci.insight.140532PubMed 32974048

  19. 19

    Coskun T, et al. (2018). Mol Metab

    DOI: 10.1016/j.molmet.2018.09.009

  20. 20

    Samms RJ, et al. (2021). J Clin Invest

    DOI: 10.1172/JCI146353PubMed 34003802

  21. 21

    El K, et al. (2023). Nat Metab

    DOI: 10.1038/s42255-023-00811-0PubMed 37277609

  22. 22

    Regmi A, et al. (2024). Cell Metab

    DOI: 10.1016/j.cmet.2024.05.010PubMed 38878772